Insulet

YTD

ALL

Trade Insulet 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PODD

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals.

CEO

Ashley A. McEvoy

CEOAshley A. McEvoy

Employees

5,400

Employees5,400

Headquarters

Acton, Massachusetts

HeadquartersActon, Massachusetts

Founded

2000

Founded2000

Employees

5,400

Employees5,400

PODD Key Statistics

Market cap

9.78B

Market cap9.78B

Price-Earnings ratio

26.55

Price-Earnings ratio26.55

Dividend yield

—

Dividend yield—

Average volume

1.68M

Average volume1.68M

High today

$143.30

High today$143.30

Low today

$140.23

Low today$140.23

Open price

$140.46

Open price$140.46

Volume

1.62M

Volume1.62M

52 Week high

$354.88

52 Week high$354.88

52 Week low

$126.40

52 Week low$126.40

Stock Snapshot

As of today, Insulet(PODD) shares are valued at $140.96. The company's market cap stands at 9.78B, with a P/E ratio of 26.55.

During the trading session on 2026-10-16, Insulet(PODD) shares reached a daily high of $143.30 and a low of $140.23. At a current price of $140.96, the stock is +0.5% higher than the low and still -1.6% under the high.

Trading activity shows a volume of 1.62M, compared to an average daily volume of 1.68M.

The stock's 52-week range extends from a low of $126.40 to a high of $354.88.

PODD News

MarketWatch 2d

Insulet Corp. stock underperforms Wednesday when compared to competitors - MarketWatch

...

Simply Wall St 4d

Insulet Rolls Out Omnipod Discover Nationwide, Is The Stock Still Cheap?

Insulet (PODD) just moved Omnipod Discover from limited rollout to full U.S. market release, putting its web based diabetes data platform in front of every Omni...

TipRanks 4d

Insulet announces U.S. full market release of Omnipod Discover

Insulet (PODD) announced the U.S. full market release of Omnipod Discover. “The future of diabetes care is not just about generating more data, it’s about makin...

Analyst ratings

55%

of 29 ratings

Buy

55.2%

Hold

44.8%

Sell

More PODD News

Simply Wall St 6d

Revenue Outlook Raised Could Be A Game Changer For Insulet Stock

Insulet reported 23% year over year revenue growth to US$802 million, driven by Omnipod demand across US and international markets, and raised its 2026 revenue...

People also own

Based on the portfolios of people who own PODD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.